{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Medication', 'No use within the following time intervals prior', 'to Screening', 'Inhaled Corticosteroids (ICS)', 'Inhaled Corticosteroids (ICS)/Inhaled long-acting', 'betaz-agonist (LABALABA) combinations', '(eg.fluticasone/salmeterol, mometasone', 'furoate/formoterol fumarate, budesonide/formoterol', 'fumarate; fluticasone furoate/vilanterol', 'Use as maintenance treatment in the 3 months prior', 'Phosphodiesterase 4 (PDE4) inhibitors (roflumilast)', 'to Visit 1 is not permitted.', 'LABA (e.g., indacaterol, olodaterol)', 'Maintenance treatment is defined as use for 14', 'consecutive days (at any time in the 3 months prior', 'Long acting muscarinic antagonists\u00b2 (LAMA) (eg', 'to Visit 1).', 'umeclidinium, aclidinium, glycopyrronium)', 'LAMA/LABA combinations', 'Theophyllines', 'Sodium cromoglycate and nedocromil sodium', 'Anti-leukotrienes', 'Long term antibiotic therapy', 'Participants receiving antibiotics for long term', 'therapy are not eligible for the study.', '(Antibiotics are allowed for the short term treatment', '(<14 days) of an exacerbation or for short term', 'treatment (14 days) of other acute infections during', 'the study)', 'Systemic, oral, parenteral corticosteroids', '30 days', '(During the study oral/systemic corticosteroids may', 'be used for 14 days to treat COPD', 'exacerbations/pneumonia)', 'Intra-articular injections are allowed', 'Any other investigational drug', '30 days or 5 half lives whichever is longer.', '1 (rescue albuterol/salbutamol will be provided and is permitted during the study)', '2', 'Does not include tiotropium, which must be taken for at least 3 months prior to screening.', '46']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '6.3.', 'Randomisation Criteria', 'At the end of the run-in period (Visit 2), study participants must fulfil the following', 'additional criteria in order to be randomised into the study and enter the treatment period.', '1. CAT score at Randomisation (Visit 2)', 'Participants with CAT score <10 at Randomisation (Visit 2 2) will be excluded.', '2. Compliance with run-in study medication', 'Compliance with each run-in study medication will be assessed by the', 'Investigator, any participant <80% or >120% compliant with either of the two', 'inhalers (ELLIPTA or Handihaler) will be excluded.', '3. COPD exacerbation or pneumonia', 'Participants that experiences a moderate or a severe COPD exacerbation or', 'pneumonia during the run-in period will be excluded.', '4. Changes in COPD medication', 'Any participant that requires a change in COPD medication from tiotropium', '(18 mcg) and rescue medication (albuterol/salbutamol) during the run-in period', 'will be excluded. This includes a temporary change in COPD medication.', '6.4.', 'Lifestyle Restrictions', 'Participants should refrain from smoking for 1 hour prior to each pulmonary function', 'test.', 'Participants should abstain from drinking beverages with high levels of caffeine such', 'as tea and coffee for 2 hours prior to each pulmonary function test.', '6.5.', 'Pre-screening/Screening/Run-in/Randomisation Failures', 'A participant will be assigned a participant number at the time the informed consent is', 'signed at Visit 0.', 'The study site will be responsible for reporting pre-screen failures. The following', 'information will be collected in the electronic case report form (eCRF) for participants', 'who are pre-screen failures: demographic information including race, age and gender;', 'participant number; SAE information only for any SAE considered to be related to study', 'participation.', 'A minimal set of information is required to ensure transparent reporting of screening/run-', 'in/randomisation failure participants to meet the Consolidated Standards of Reporting', 'Trials (CONSORT) publishing requirements and to respond to queries from regulatory', 'authorities. Minimal information includes demography, screening/run-in/randomisatior', 'failure details, eligibility criteria, and any SAEs. Further details are provided in the study-', '47']\n\n###\n\n", "completion": "END"}